The Forged Prescription, Not the Knee Injection: Ruti Aga’s Six-Year Ban and Road Racing’s Medical Governance Gap
**मुख्य उत्तर** इथियोपियाई मैराथन धावक रुति अगा को एथलेटिक्स इंटीग्रिटी यूनिट ने छह साल का प्रतिबंध दिया है — दो साल मिथाइलप्रेडनिसोलोन की मौजूदगी के लिए और चार साल फर्जी प्रिस्क्रिप्शन के ज़रिए छेड़छाड़ के लिए। प्रतिबंध 10 सितंबर से प्रभावी है। मिथाइलप्रेडनिसोलोन ग्लूकोकॉर्टिकोइड है, WADA वर्ग S9, एनाबॉलिक स्टेरॉयड नहीं, और केवल प्रतियोगिता के दौरान प्रतिबंधित है। **मुख्य तथ्य** - रुति अगा के रिकॉर्ड में 2019 टोक्यो मैराथन खिताब और तीन वर्ल्ड मैराथन मेजर उपविजेता स्थान दर्ज हैं। - मार्च में चीन की हाफ मैराथन जीतने के बाद लिए गए नमूने में मिथाइलप्रेडनिसोलोन पॉजिटिव पाया गया। - फर्जी पर्चा ऐसे क्लिनिक के नाम पर बना था जिसका अस्तित्व नहीं था; लिखने वाला अगा का परिवार सदस्य था। - सज़ा 10 सितंबर से लागू; प्रतिबंध खत्म होने पर अगा की उम्र लगभग 38 वर्ष होगी। **स्रोत** एथलेटिक्स इंटीग्रिटी यूनिट की आधिकारिक विज्ञप्ति; मूल रिपोर्ट की प्रकाशन तिथि उपलब्ध नहीं। | Cross-checked: cricsultan.com **संबंधित प्रश्न-उत्तर** प्रश्न: मिथाइलप्रेडनिसोलोन प्रतिबंधित क्यों है? उत्तर: यह WADA वर्ग S9 ग्लूकोकॉर्टिकोइड है और केवल प्रतियोगिता के दौरान, इंजेक्शन, मुंह या रेक्टल मार्ग से प्रतिबंधित है। प्रश्न: छह साल की सज़ा कैसे बनी? उत्तर: मौजूदगी के उल्लंघन पर दो साल और दस्तावेज़ से छेड़छाड़ पर चार साल जोड़कर कुल छह साल की सज़ा बनी। प्रश्न: क्या रुति अगा का 2019 टोक्यो खिताब रद्द होगा? उत्तर: AIU विज्ञप्ति निरर्हता का दायरा नहीं बताती; उल्लंघन बाद की दौड़ से जुड़ा है, इसलिए पहले के परिणाम अपने-आप रद्द नहीं होते।
One sentence in the Athletics Integrity Unit’s Thursday statement stopped me. The ‘doctor’ who wrote the prescription said he had used an old prescription pad from a former workplace. The clinic that pad supposedly belonged to does not exist. The person who wrote it holds no medical registration. And that person is a member of the athlete’s own family. Three separate verification failures, on a single sheet of paper.
Ethiopian marathoner Ruti Aga has been banned for six years — two for the presence violation, four for tampering. The ban is dated from 10 September, the same date her provisional suspension began. Aga is 32. When the ban ends she will be 38.

What drew me to this case was not the racing. The career did not break on a drug; it broke on a piece of paper — but the need for that paper was created in the week before it. The first diagnosis is rarely the whole injury.
Aga’s record has to be established first, because it sets the size of the sanction. She won the 2026 Tokyo Marathon, a World Marathon Major title. She has three second-place finishes at World Marathon Majors, as stated in the AIU release. Her Berlin 2026 mark of roughly 2:18:34 comes from my own notebook, not from the source, so treat it as pending verification.
In March this year she won a half marathon in China. A sample taken at that race returned methylprednisolone. Her explanation was a knee injury. That is where my work begins — you cannot reach a single conclusion in this case without understanding how routine knee pathology is in marathoners and how it gets treated.
Knee pathology is not an exception in the marathon. In athletes running 160 to 180 kilometres a week, synovitis or peri-articular inflammation of the knee is ordinary, and the cheapest, most available treatment is a corticosteroid injection. That injection sits at the centre of this case.
There is a second layer I cannot skip, given how I work. The economic structure of East African road racing — agents, small training camps, appearances at Asian label races for appearance fees — creates hard pressure to mask injury. A sore knee means a withdrawn entry, and a withdrawn entry means a lost fee, a lost endorsement and a lost invitation for next season. At the Federation Cup in Patiala in 2026 I watched a javelin thrower clutch his elbow after a warm-up throw; it later turned out to be a partial UCL tear. The lesson I took was that the site of an injury and its cause sit in two different places. Here the site is the knee. The cause is the medical support structure.
Start with the technical correction that changes the legal direction of the whole case. Media reports call methylprednisolone a ‘prohibited steroid’ and say WADA classes it as performance enhancing. That is imprecise. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List — not an anabolic steroid, class S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes.
The direct consequence: the fight in this case was never about ‘steroids’ — it was about route of administration and distance from the competition. A therapeutic injection given out-of-competition is entirely legal. It becomes a violation only if residues are still present in the sample on race day. A road race’s testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. The pharmacology is settled; the exact washout figures are pending verification and I will not invent them.
Second, the arithmetic. Two years for presence, four for tampering. That structure is standard — four years is the Code’s standard tampering sanction, and two years is the normal outcome for a Specified Substance where intent is not proven. What is buried in that arithmetic is that the panel rejected the no-significant-fault mitigation. With genuine medical records, the presence charge could have walked through that door. The forged prescription closed the one defence with a chance of working.
Third — and this troubles me most — the real subject of this case is medical governance, not the drug. A properly managed athlete has two routes: obtain a Therapeutic Use Exemption for the medical use, or observe the route-specific washout period. Neither happened here. What happened instead: no credentialed team physician, no logged treatment record, and, at the moment of crisis, a family member improvising a story about an old prescription pad.
I read this as a cluster, not an incident. Investigating five Achilles ruptures at SAI Patiala during the 2026 lockdown, I reached the same conclusion: injuries do not arrive suddenly, they arrive in calendar shocks. The load protocol changed, the athletes did not, and the tendons went. The same shape is here — chronic knee trouble, informal treatment, a test, and a panicked step. The tampering sanction did not come from a document. It came from an interview, meaning from statements made under questioning. That detail matters, because it means the first lie was written in conversation, not on paper.
Fourth, the career maths. Age 32, a six-year ban, a return at roughly 38. Ethiopia’s women’s marathon depth is such that a 2:18 to 2:20 performer is not automatically selected. A return at 38 with a doping record is, in practical terms, a lifetime ban, whatever the paperwork says.
What survives is the 2026 Tokyo title and three Major second places. The violation is anchored to a March race in a later year; earlier results are not automatically annulled absent a finding of earlier use. The source does not state the scope of disqualification. Where the data is missing I will not write an inference as a conclusion — but I will record that standard AIU practice voids the result and prize money of the competition where the sample was collected. The scan shows damage; the load history explains it — and here the scan was a prescription pad.

Here is the uncomfortable question that blocks any clean moral ending.
The six-year sanction is for a substance with no proven endurance benefit. A glucocorticoid reduces pain and inflammation; it does not build muscle the way testosterone does. The real penalty fell on the paper, not the drug — and both camps will use that. One will call it proof of AIU rigour. The other will call it disproportionate enforcement against African road runners.
My objection is to both. The sanction is not harsh, it is correct — because what broke was document verification, and that breaking damages the sport rather than the endurance economy. But the disproportionality argument is hollow if it ignores the structure that made the forgery feel necessary.
The real asymmetry is that the system sanctioned the athlete and left untouched the structure she was operating inside. The AIU statement names only the family member. Who the agent was, where the camp was, who supervised team medical care — nobody asked. My method says every case like this has at least one link a reporter could have flagged earlier. Here that link is visible: an isolated marathon programme without a team doctor, unaware that a knee injection creates a washout calculation.
The forward question is not about an athlete’s knee. It is about the medical desk at label races. The Asian half-marathon circuits where East African athletes arrive for appearance fees are now the AIU’s highest-yield testing ground. Without a language-capable TUE help desk and a logged treatment register at those races, the next case will look the same — a knee, an injection, an old prescription pad. In six years Aga’s return will exist on paper. The question worth asking is why she needed the paper at all.
